Total Payments
$3.6M
2024 Payments
$497,213
Companies
51
Transactions
5,435
Medicare Patients
5,057
Medicare Billing
$5.0M
Payment Breakdown by Category
Other$2.8M (77.7%)
Travel$456,039 (12.5%)
Consulting$266,418 (7.3%)
Food & Beverage$90,122 (2.5%)
Education$401.94 (0.0%)
Gifts$40.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 892 | 51.4% |
| Honoraria | $956,315 | 444 | 26.2% |
| Travel and Lodging | $456,039 | 1,313 | 12.5% |
| Consulting Fee | $266,418 | 115 | 7.3% |
| Food and Beverage | $90,122 | 2,644 | 2.5% |
| Education | $401.94 | 25 | 0.0% |
| Grant | $239.52 | 1 | 0.0% |
| Gift | $40.59 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $682,814 | 689 | $0 (2023) |
| ABBVIE INC. | $583,892 | 899 | $0 (2024) |
| Amgen Inc. | $385,974 | 683 | $0 (2024) |
| Horizon Pharma plc | $332,693 | 325 | $0 (2018) |
| Lilly USA, LLC | $300,332 | 531 | $0 (2024) |
| Celgene Corporation | $228,458 | 279 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $189,005 | 218 | $0 (2024) |
| GlaxoSmithKline, LLC. | $180,164 | 183 | $0 (2024) |
| GENZYME CORPORATION | $154,899 | 203 | $0 (2024) |
| UCB, Inc. | $151,620 | 313 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $497,213 | 656 | Amgen Inc. ($114,633) |
| 2023 | $485,141 | 655 | AbbVie Inc. ($122,166) |
| 2022 | $573,333 | 835 | Horizon Therapeutics plc ($142,244) |
| 2021 | $433,151 | 611 | Horizon Therapeutics plc ($202,531) |
| 2020 | $298,980 | 504 | Horizon Therapeutics plc ($130,459) |
| 2019 | $586,206 | 842 | Horizon Therapeutics plc ($120,927) |
| 2018 | $446,285 | 756 | Horizon Pharma plc ($185,124) |
| 2017 | $324,471 | 576 | Horizon Pharma plc ($147,569) |
All Payment Transactions
5,435 individual payment records from CMS Open Payments — Page 1 of 218
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $3.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/15/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $76.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $138.74 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Rheumatology | ||||||
| 12/13/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $312.98 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $16.98 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $8.14 | General |
| Category: Immunology | ||||||
| 12/09/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Rheumatology | ||||||
| 12/06/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $146.20 | General |
| Category: Bone Health | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $10.90 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $105.27 | General |
| Category: Immunology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/03/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| 12/03/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Honoraria | Cash or cash equivalent | $3,412.50 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,591 | 257,179 | $5.1M | $1.6M |
| 2022 | 21 | 1,556 | 239,348 | $3.3M | $1.5M |
| 2021 | 21 | 1,080 | 182,416 | $2.4M | $1.2M |
| 2020 | 15 | 830 | 93,148 | $1.4M | $672,063 |
Total Patients
5,057
Total Services
772,091
Medicare Billing
$5.0M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 39 | 172,720 | $2.5M | $809,822 | 32.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 35 | 25,352 | $845,115 | $266,046 | 31.5% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 20 | 52,400 | $704,400 | $199,321 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 563 | 1,201 | $324,415 | $89,616 | 27.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 109 | 792 | $273,240 | $77,794 | 28.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 28 | 2,880 | $155,760 | $52,683 | 33.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 230 | 356 | $129,584 | $41,493 | 32.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 50 | 358 | $67,662 | $19,304 | 28.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 97 | 97 | $39,780 | $10,987 | 27.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 75 | 75 | $39,075 | $10,813 | 27.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 157 | $17,270 | $3,351 | 19.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 28 | 177 | $15,045 | $2,057 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 55 | $10,120 | $2,024 | 20.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 90 | 145 | $9,280 | $1,458 | 15.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 21 | $5,670 | $1,014 | 17.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 15 | 16 | $2,800 | $835.56 | 29.8% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 71 | 108 | $2,369 | $431.31 | 18.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 16 | 34 | $1,360 | $264.26 | 19.4% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 34 | 221 | $1,105 | $90.28 | 8.2% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 11 | 14 | $133.00 | $36.79 | 27.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 28 | 156,220 | $1.2M | $725,161 | 58.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 34 | 23,546 | $543,504 | $249,185 | 45.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 17 | 53,800 | $591,800 | $242,915 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 480 | 950 | $256,500 | $70,705 | 27.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 95 | 593 | $204,585 | $62,155 | 30.4% |
About Dr. Sanjay Chabra, D.O
Dr. Sanjay Chabra, D.O is a Rheumatology healthcare provider based in El Paso, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316916125.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sanjay Chabra, D.O has received a total of $3.6M in payments from pharmaceutical and medical device companies, with $497,213 received in 2024. These payments were reported across 5,435 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.9M).
As a Medicare-enrolled provider, Chabra has provided services to 5,057 Medicare beneficiaries, totaling 772,091 services with total Medicare billing of $5.0M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location El Paso, TX
- Active Since 03/15/2006
- Last Updated 10/06/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1316916125
Products in Payments
- KRYSTEXXA (Biological) $459,532
- RAYOS (Drug) $425,196
- Otezla (Drug) $299,405
- RINVOQ (Biological) $278,734
- SAPHNELO (Biological) $183,139
- KRYSTEXXA (Drug) $159,429
- TALTZ (Drug) $155,565
- BENLYSTA (Biological) $148,425
- LUPKYNIS (Drug) $121,206
- Enbrel (Biological) $115,036
- Cimzia (Drug) $107,620
- ACTHAR (Biological) $89,891
- KEVZARA (Biological) $84,870
- XELJANZ (Drug) $73,801
- COSENTYX (Biological) $55,959
- TAVNEOS (Drug) $52,762
- SKYRIZI (Biological) $50,827
- KEVZARA (Drug) $48,320
- OLUMIANT (Drug) $48,033
- Humira (Biological) $46,937
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in El Paso
Dr. Franchesca Cruz Perez, M.d, M.D
Rheumatology — Payments: $11,155
Rheumatology $11,155
Dr. Luis Salayandia, M. D, M. D
Rheumatology — Payments: $10,513
Rheumatology $10,513
Yasmin Sabet, M.d, M.D
Rheumatology — Payments: $4,672
Rheumatology $4,672
Rosario Nadorra, Md, MD
Rheumatology — Payments: $1,158
Rheumatology $1,158
Robert Abresch, M.d, M.D
Rheumatology — Payments: $937.84
Rheumatology $937.84
Zeeshan Afzal, M.d, M.D
Rheumatology — Payments: $851.24
Rheumatology $851.24